Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan

  1. JPMA MIDD Task force
  2. Tomohiro Sasaki
  3. Takayuki Katsube
  4. Seiichi Hayato
  5. Shingo Yamaguchi
  6. Jun Tanaka
  7. Hiroki Yoshimatsu
  8. Yushi Nakanishi
  9. Atsushi Kitamura
  10. Hirotaka Watase
  11. Hideki Suganami
  12. Nobushige Matsuoka
  13. Chihiro Hasegawa
Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1007/s10928-024-09954-3
  2. Version published to 10.21203/rs.3.rs-4615728/v1 on Research Square